Business Context and Reporting Period
This Form 8-K filing by Ra Medical Systems, Inc. (RMED) reports on events occurring on November 14, 2020, and effective November 16, 2020. The filing details the implementation of a reverse stock split following shareholder approval at the 2020 Annual Meeting.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Company effected a 1-for-25 reverse stock split effective at 4:01 p.m. Eastern time on November 16, 2020.
- Share Count Reduction: The number of issued and outstanding shares of Common Stock was reduced from approximately 73.0 million to approximately 2.9 million.
- Trading Status: Common Stock began trading on the New York Stock Exchange on a post-split basis on November 17, 2020, under the symbol "RMED" with a new CUSIP number (74933X203).
- Authorized Shares: The split increased the number of authorized shares available for issuance relative to outstanding shares, as the total authorized count was not reduced.
Guidance, Outlook, and Unusual Items
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies beyond the mechanics of the stock split. The document notes that no fractional shares were issued; instead, stockholders entitled to fractional shares received cash payments based on the closing sale price on the effective date. Additionally, equity awards and exercise prices were proportionately adjusted.
Investor Verification Checklist
- Verify the new CUSIP number (74933X203) for post-split trading.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-25 ratio.
- Check for cash payments received in lieu of fractional shares if the pre-split holding was not evenly divisible by 25.
- Review the adjusted exercise prices and share counts for any outstanding equity awards or options.